Listar por tema "monoclonal antibody"
Mostrando ítems 21-32 de 32
-
Radiolabeled mAbs as Molecular Imaging and/or Therapy Agents Targeting PSMA
(2018)Molecular imaging and therapy is a rapidly evolving field in research and clinical medicine. The use of the exciting and attractive properties of radioisotopes for imaging and therapy has made Nuclear Medicine very significant ... -
A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures
(2020)Background:Romosozumab is a bone-forming antibody that increases bone formation and decreases bone resorption. We conducted a double-blinded, randomized, phase-2, dose-finding trial to evaluate the effect of romosozumab ... -
Repeatability and reproducibility of the interpretation of intradermal test results in dogs with atopic dermatitis
(2022)Background – There is lack of studies evaluating the repeatability and reproducibility of the interpretation of intradermal testing in dogs with atopic dermatitis (AD). Objectives – To evaluate the repeatability and ... -
Romosozumab in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture: A Randomized Phase-2 Study
(2020)BACKGROUND: Romosozumab is an antibody that binds and inhibits sclerostin, thereby increasing bone formation and decreasing bone resorption. A double-blinded, randomized, phase-2, dose-finding trial was performed to evaluate ... -
The second greek–israeli symposium on autoimmunity and rheumatology: Success through synergy
(2019)[No abstract available] -
Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis
(2016)Systemic sclerosis (SSc) is a multisystem disease characterized by extensive collagen deposition in skin and internal organs, fibrointimal microvasculopathy, and activation of the immune system. T cells and B cells can ... -
Successful response in a case of severe pustular psoriasis after interleukin-1β inhibition
(2017)Generalized pustular psoriasis (GPP) is a severe type of psoriasis accompanied by systemic and often life-threatening manifestations. The efficacy of the interleukin (IL)-1 antagonist anakinra in cases of GPP underscores ... -
Systemic sclerosis: From pathogenesis towards targeted immunotherapies
(2012)Systemic sclerosis (SSc), a chronic disease with widespread collagen deposition, has three pathogenetic facets: immune activation, microvasculopathy and fibroblast activation. Immune activation and microvasculopathy occur ... -
Tocilizumab improves oxidative stress and endothelial glycocalyx: A mechanism that may explain the effects of biological treatment on COVID-19
(2020)We investigated the effects of tocilizumab on endothelial glycocalyx, a determinant of vascular permeability, and myocardial function in rheumatoid arthritis (RA). Eighty RA patients were randomized to tocilizumab (n = 40) ... -
Validated analysis of HIF-1α expression in cancer cells using a controlled and comparative immunoassay
(2010)The immunoreactivity of hypoxia inducible factor 1 α (HIF-1α) has been considered a reliable indicator of the HIF-1 pathway activation in tissue hypoxia. However, HIF-1α immunoreactivity has been evaluated with different ... -
Vascular endothelial growth factor (VEGF) in pleural effusions
(2007)Pleural effusion is a common clinical problem in everyday clinical practice. Vascular endothelial growth factor (VEGF) is a 34-45 kDa homodimeric glycoprotein, which is a potent mediator of angiogenesis and vascular ... -
Viruses and Multiple Sclerosis: From Mechanisms and Pathways to Translational Research Opportunities
(2017)Viruses are directly or indirectly implicated in multiple sclerosis (MS). Here, we review the evidence on the virus-related pathophysiology of MS, introduce common experimental models, and explore the ways in which viruses ...